Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
|Articles|January 6, 2010
Oncology NEWS International
- Oncology NEWS International Vol 18 No 12
- Volume 18
- Issue 12
Cetuximab plus chemo boosts surgery in advanced colon ca
Adding cetuximab (Erbitux) to neoadjuvant chemotherapy shrank tumors enough to increase the success of curative surgery in colon cancer patients with inoperable metastatic liver lesions, according to the CELIM trial conducted in Germany and Austria.
Advertisement
Adding cetuximab (Erbitux) to neoadjuvant chemotherapy shrank tumors enough to increase the success of curative surgery in colon cancer patients with inoperable metastatic liver lesions, according to the CELIM trial conducted in Germany and Austria.
Patients were randomized to cetuximab treatment with FOLFOX6 or with FOLFIRI. Treatment with cetuximab resulted in high tumor response rates and a 28% increase in the proportion of tumors that were amenable to surgery. Ultimately, surgery was achieved in 34% of the patients. Because of cetuximab treatment, 60% of tumors were deemed resectable vs 32% at the start of the study (Lancet Oncology online, November 24, 2009).
Articles in this issue
almost 17 years ago
OB/GYN revises suggested age for cervical ca screeningalmost 17 years ago
Brain tumor gene mapping project launches in Seattlealmost 17 years ago
PET timing guides radiation RX in lung caalmost 17 years ago
Experts take umbrage with federal panel change to age for mammo screeningalmost 17 years ago
Radiosurgery gains role for noncancer applicationsalmost 17 years ago
New radiotracer shows early treatment response for patients with lung canceralmost 17 years ago
Addition of rituximab improves OS in chronic lymphocytic leukemiaalmost 17 years ago
Micromet scores multiple development dealsalmost 17 years ago
New agents for lymphoma take center stagealmost 17 years ago
Vaccines plus screening could end cervical caAdvertisement
Related to this article
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
3
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
4
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
5